Repare Therapeutics 주식 (NASDAQ: RPTX)

Repare Therapeutics (NASDAQ:RPTX) 주식

Repare Therapeutics

Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.

Cathie Wood Smelling AI Opportunity? Ark Invest Buys Tempus AI Dip, Scoops Up Over $13 M Worth Of Stock

Equities

News

Markets

ETFs

ARKF

ARKG

ARKK

ARKW

CDNA

GTLB

IBTA

NTLA

PATH

PRME

RBLX

RPTX

2025년 3월 14일 금요일, 캐시 우드가 이끄는 아크 인베스트가 깃랩(NASDAQ:GTLB), 인텔리아 테라퓨틱스(NGM:NTLA), 프라임 메디슨(NGM:PRME), 유아이패스(NYSE:PATH), 아이보타(NYSE:IBTA), 로블록스(NYSE:RBLX), 리페어 테라퓨틱스(NASDAQ:RPTX) 및 케어DX(NASDAQ:CDNA)에 대해 큰 매매를 했다.

아크 인베스트: 유아이패스와 로블록스 주식을 계속 처분, 깃랩과 아이보타를 매수

Repare Therapeutics Inc

Needham analyst Bernie McTernan reiterates AppLovin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) from Hold to Hold.

Reiteration

Analyst Ratings

Needham Reiterates Hold on AppLovinto Hold

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates Rallybio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLYB#NASDAQ">RLYB</a>) with a Buy and maintains $5 price target.

Price Target

RLYB

HC Wainwright & Co. Reiterates Buy on Rallybio, Maintains $5 Price Target

Evercore ISI Group analyst Steve Sakwa upgrades SL Green Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLG#NYSE">SLG</a>) from In-Line to Outperform and lowers the price target from $74 to $73.

Upgrades

Evercore ISI Group Upgrades SL Green Realty to Outperform, Lowers Price Target to $73

GRMN

Garmin Says G3000 PRIME Integrated Flight Deck Selected By Pilatus For Its New PC-12 PRO Aircraft

MDIA

Spectral AI Reports Results Of Performance Of Its DeepView System In Connection With Completion Of Its Burn Validation Study

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Zentalis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZNTL#NASDAQ">ZNTL</a>) with a Buy and maintains $10 price target.

ZNTL

HC Wainwright & Co. Reiterates Buy on Zentalis Pharma, Maintains $10 Price Target

PBGENE-HBV is the first-ever investigational in vivo gene editing therapy cleared to enter clinical trials for the treatment of chronic hepatitis B in the United States (U.S.) –
- IND clearance represents a significant regulatory milestone for PBGENE-HBV –
- Company to expand its Phase 1 ELIMINATE-B study to the U.S., joining world-class clinical sites in Moldova, Hong Kong, and New Zealand where strong clinical execution is currently underway –

DTIL

Precision BioSciences Achieves Regulatory Milestone As FDA Clears IND For First-in-Class PBGENE-HBV Gene Editing Therapy For Chronic Hepatitis B

Founder and Chairman of the Board, Michael Heffernan, and Board Member, Gwen A. Melincoff, will retire from Collegium's Board at the Annual General Meeting (AGM) on May 15, 2025, and Gino Santini, the Board's Lead Independent Director, will become Chairman.&nbsp;

Management

COLL

Collegium Names Gino Santini As Chairman; Michael Heffernan And Gwen Melincoff To Retire From Board

HROW

Harrow Unveils VEVYE Access For All Initiative

Orphan Drug Designation follows positive Phase 1 data presented at the 12th International Workshop on Waldenström Macroglobulinemia
First-in-class Bruton's tyrosine kinase (BTK) degrader NX-5948 assigned nonproprietary name "bexobrutideg" in newly named degrader class of drugs

Biotech

Health Care

General

NRIX

The FDA Has Granted Orphan Drug Designation To Nurix Therapeutics' Bexobrutideg (NX-5948) For The Treatment Of Waldenström Macroglobulinemia

D. Boral Capital analyst Jason Kolbert initiates coverage on Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) with a Buy rating and announces Price Target of $9.

Initiation

PSTV

D. Boral Capital Initiates Coverage On Plus Therapeutics with Buy Rating, Announces Price Target of $9

Patients in this cohort are receiving [212Pb]VMT01 at 1.5 mCi in combination with nivolumab, a PD-1 blocking antibody developed and marketed by Bristol Myers Squibb as Opdivo&#xAE;. Patients in earlier cohorts received [212Pb]VMT01 as monotherapy. Initial results from the earlier cohorts were previously presented at the <a href="https://www.globenewswire.com/Tracker?data=lbnqdoEdOBXDI0tazCF7O6Gm7aX960Z1DPz2hC7XVYWhydPL2gB28iRuKsyv7ZVPFqojoIIM72ZkxXaHKLxmJt6PtL3nFc73iqhtgo0Yz-LnEZm3oXkwl2rnwMjMCskTVi4Poh6LA4DWRL6fyrFyOWegGsn_SutWUndN7X518RZuVXN46SyFeCQbKYM-LL2KR7mx-p2m7KH6VzfFKZWpEg==">21st International Congress of the Society for Melanoma Research</a> (SMR) in October 2024.

CATX

Perspective, Therapeutics Has Dosed The First Patient In A New Cohort Of A Phase 1/2a Trial Evaluating The Safety Of [212Pb]VMT01, A Targeted Alpha-particle Therapy, In Patients With Histologically Confirmed Melanoma And Positive Melanocortin 1 Receptor Imaging Scan

TVTX

Travere Submits sNDA To FDA For Seeking Priority Review For Traditional Approval Of FILSPARI For Focal Segmental Glomerulosclerosis Treatment

Guidance

SAIC

Science Applications Intl Revised FY26 Revenue Outlook To $7.60B-$7.75B From $7.55B-$7.75B (Vs. Cons. $7.644B), Adj. EPS To $9.10 - $9.30 From $8.90 - $9.10 (vs. Cons. Of $9.07)

<ul>
<li>Once-daily, steroid-free topical treatment designed to rapidly reduce itch and proactively support long term disease control</li>
<li>Rapid and significant improvements in disease clearance with ZORYVE cream with children and adults reaching validated Investigator Global Assessment – Atopic Dermatitis (vIGA-AD) Success at week 4, with significant improvements seen as early as week 1</li>
<li>Demonstrated efficacy and tolerability in treating facial involvement in AD, which affected 42% of trial participants</li>
<li>Shown to deliver sustained improvement in disease control for up to 56 weeks of treatment</li>
</ul>

ARQT

The Health Canada Has Approved Arcutis' Approved Zoryve (Roflumilast Cream 0.15%), For The Treatment Of Mild To Moderate Atopic Dermatitis In Adults And Children Ages 6 Years And Older

BECN

QXO In Discussions To Acquire Beacon Roofing Supply For $124.35 Per Share In All-Cash Deal Worth ~$11B

D. Boral Capital analyst Jesse Sobelson maintains FiscalNote Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOTE#NYSE">NOTE</a>) with a Buy and maintains $3.75 price target.

NOTE

D. Boral Capital Maintains Buy on FiscalNote Holdings, Maintains $3.75 Price Target

Contracts

PRSO

Peraso Receives $3.6M Purchase Order For Its mmWave Devices From A Provider Of Wireless Networking Systems

<ul>
<li>On track for year end 2025 BLA submission for accelerated approval of 5 mg/kg every six weeks of del-zota in DMD44</li>
<li>Consistent favorable safety and tolerability across del-zota dose cohorts&nbsp;</li>
<li>Plan to present functional data in fourth quarter of 2025</li>
</ul>

Avidity Biosciences Announced Del-Zota Topline Data From The Phase 1/2 Explore44 Trial For Duchenne Muscular Dystrophy Amenable To Exon 44 Skipping, Demonstrating Consistent, Statistically Significant Improvements In Dystrophin, Exon Skipping And Creatine Kinase As Well As Favorable Safety And Tolerability

Following the close of the transaction, the Company expects its outstanding share count to be reduced by approximately 12% and the transaction is expected to close on or around March 18, 2025.
Concurrent with the announced stock transaction, the Company also announced that Jonathan Seiffer will step down from the Board of Directors, effective immediately.
 &nbsp;

Buybacks

ASLE

AerSale To Repurchase Approximately 6.428M Shares Of Stock From Its Long-term Private Equity Sponsor Leonard Green & Partners At Negotiated Price Of $7.00 Per Share

Press Releases

Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor

Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial

Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results

Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib

Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial

Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial

Opinion

How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options

Repare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost Reductions

Repare Therapeutics Provides Business and Clinical Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Comments

Repare Therapeutics

뉴스

파트너 / 기고자

벤징가 글로벌